205 related articles for article (PubMed ID: 37361535)
21. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
22. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study.
Pinola P; Lashen H; Bloigu A; Puukka K; Ulmanen M; Ruokonen A; Martikainen H; Pouta A; Franks S; Hartikainen AL; Järvelin MR; Morin-Papunen L
Hum Reprod; 2012 Nov; 27(11):3279-86. PubMed ID: 22933528
[TBL] [Abstract][Full Text] [Related]
23. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
24. Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome.
Chen CI; Hsu MI; Lin SH; Chang YC; Hsu CS; Tzeng CR
Gynecol Endocrinol; 2015 Apr; 31(4):264-8. PubMed ID: 25423261
[TBL] [Abstract][Full Text] [Related]
25. Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.
Velazquez ME; Millan AL; Rojo M; Abruzzese GA; Cocucci SE; Iglesias Molli AE; Frechtel GD; Motta AB; Cerrone GE
Front Endocrinol (Lausanne); 2021; 12():604215. PubMed ID: 34054718
[TBL] [Abstract][Full Text] [Related]
26. Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
Lam UD; Lerchbaum E; Schweighofer N; Trummer O; Eberhard K; Genser B; Pieber TR; Obermayer-Pietsch B
Gene; 2014 Mar; 537(2):245-52. PubMed ID: 24388959
[TBL] [Abstract][Full Text] [Related]
27. [Body composition and polycystic ovary syndrome].
Zabuliene L; Tutkuviene J
Medicina (Kaunas); 2010; 46(2):142-57. PubMed ID: 20440089
[TBL] [Abstract][Full Text] [Related]
28. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
29. Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome.
Zhang H; Wang W; Zhao J; Jiao P; Zeng L; Zhang H; Zhao Y; Shi L; Hu H; Luo L; Fukuzawa I; Li D; Li R; Qiao J
Front Endocrinol (Lausanne); 2022; 13():1085656. PubMed ID: 36699018
[TBL] [Abstract][Full Text] [Related]
30. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome.
Huang R; Zheng J; Li S; Tao T; Ma J; Liu W
Acta Obstet Gynecol Scand; 2015 May; 94(5):494-500. PubMed ID: 25711494
[TBL] [Abstract][Full Text] [Related]
32. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.
Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C
Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598
[TBL] [Abstract][Full Text] [Related]
33. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
34. [Influence of weight and distribution of adipose tissue in functional hyperandrogenism].
Pasquali R; Vicennati V; Gambineri A
Contracept Fertil Sex; 1998 May; 26(5):372-5. PubMed ID: 9648381
[TBL] [Abstract][Full Text] [Related]
35. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome.
de Medeiros SF; Rodgers RJ; Norman RJ
Hum Reprod Update; 2021 Jun; 27(4):771-796. PubMed ID: 33764457
[TBL] [Abstract][Full Text] [Related]
36. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
[TBL] [Abstract][Full Text] [Related]
38. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome.
Moran LJ; Teede HJ; Noakes M; Clifton PM; Norman RJ; Wittert GA
J Endocrinol Invest; 2013 Dec; 36(11):1004-10. PubMed ID: 23812344
[TBL] [Abstract][Full Text] [Related]
39. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
[TBL] [Abstract][Full Text] [Related]
40. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
